The Conversation (0)
Catalyst Biosciences Announces Closing of Public Offering of Common Stock
Feb. 15, 2018 09:46AM PST
Pharmaceutical Investing
Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the closing of an underwritten public offering of 3,382,352 shares of its common stock, offered at a price of $34.00 per share to the public, which includes the exercise in full by the underwriters of …
Catalyst Biosciences (NASDAQ:CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications (the Company), today announced the closing of an underwritten public offering of 3,382,352 shares of its common stock, offered at a price of $34.00 per share to the public, which includes the exercise in full by the underwriters of their option to purchase an additional 441,176 shares of common stock.
As quoted in the press release:
The gross proceeds to the Company from this offering were approximately $115 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. All of the shares in the offering were sold by the Company.
JonesTrading Institutional Services LLC is acting as Sole Bookrunning Manager, Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE American:LTS) is acting as Joint Bookrunner, LifeSci Capital LLC is acting as a Lead Manager, and B. Riley FBR, Inc. is acting as a Co-Manager for the proposed offering.
